Medlive Technology Valuation
Is 2192 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
[object Object] Score0/6
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2192?
Other financial metrics that can be useful for relative valuation.
|What is 2192's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 2192's PE Ratio compare to its peers?
|Company||PE||Estimated Growth||Market Cap|
2361 Sinohealth Holdings
1515 China Resources Medical Holdings
1789 AK Medical Holdings
1501 Shanghai Kindly Medical Instruments
2192 Medlive Technology
Price-To-Earnings vs Peers: 2192 is expensive based on its Price-To-Earnings Ratio (132.5x) compared to the peer average (34.8x).
Price to Earnings Ratio vs Industry
How does 2192's PE Ratio compare vs other companies in the Asian Healthcare Services Industry?
Price to Earnings Ratio vs Fair Ratio
What is 2192's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||132.5x|
|Fair PE Ratio||34x|
Price-To-Earnings vs Fair Ratio: 2192 is expensive based on its Price-To-Earnings Ratio (132.5x) compared to the estimated Fair Price-To-Earnings Ratio (34x).
Share Price vs Fair Value
What is the Fair Price of 2192 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2192 (HK$9.78) is trading above our estimate of fair value (HK$0.71)
Significantly Below Fair Value: 2192 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
|Date||Share Price||Average 1Y Price Target||Dispersion||High||Low||1Y Actual price||Analysts|
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.